Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Dean F. Bajorin, Stéphane Culine et al.|New England Journal of Medicine|2017Cited by 3.4k
American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late EffectsJoseph R. Carver, David J. Vaughn|Journal of Clinical Oncology|2007Cited by 799
Risk of Bladder Cancer Among Diabetic Patients Treated With PioglitazoneJames D. Lewis, Brian L. Strom, Assiamira Ferrara et al.|Diabetes Care|2011Cited by 620
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upYves Fradet, Dean F. Bajorin, Joaquim Bellmunt et al.|Annals of Oncology|2019Cited by 484
Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood FlowJames Stevenson, Peter J. O’Dwyer, Mark Rosen et al.|Journal of Clinical Oncology|2003Cited by 293